GAGrant Antoine

Grant Antoine

*This is an algorithmically generated author record based on publicly available information.

Grant Antoine has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metatranscriptomics-Derived Disease Risk Scores as a Preventive, Diagnostic, and Treatment Support Tool

    by Lan Hu, Michael Bass, Eric Patridge, Matthew Molusky, Grant Antoine, Momchilo Vuyisich, Guruduth Banavar

    Background: Chronic diseases and symptom syndromes often develop after prolonged biological changes that may precede formal diagnosis. RNA-based metatranscriptomics captures active microbial and human gene expression and may provide a functional layer for disease risk evaluation. To address this translational gap, we developed and validated a Disease Risk Score (DRS) framework that integrates metatranscriptome-derived pathway activity scores from stool, saliva, and blood samples, and evaluated its potential clinical utility as an adjunct risk-evaluation tool. Methods: DRS uses disease-specific sets of pathway activity scores derived from stool and saliva microbial functions, stool and saliva microbial taxa, and blood human gene expression. For each disease, ‘not optimal’ pathway scores are aggregated into a normalized cumulative odds ratio, or cOR, using score-level odds ratios, statistical significance, and literature-supported biological relevance derived from a Development Cohort of 22,369 individuals. A cOR ≥ 5 is defined as high risk. Performance is evaluated in an independent Validation Cohort of 15,908 individuals using self-reported diseases as the reference. Disease support requires both significant cOR separation between self-reported and not-reported (Cohen’s d ≥ 0.2) and risk ratio enrichment of self-reported disease among individuals classified as high risk (95% CI of Risk Ratio > 1). Results: Of 20 initially evaluated diseases, 15 meet the prespecified validation criteria on the independent validation cohort: ADHD, anxiety, chronic fatigue syndrome, depression, GERD, hypertension, inflammatory bowel disease, IBS-C, IBS-D, insomnia, MASLD, obesity, obstructive sleep apnea, Sjögren’s syndrome, and type 2 diabetes. Five selected clinical scenarios illustrate how DRS can support clinician-mediated decision making, including IBS subtype reclassification, improved diagnostic acceptance in IBS-D, personalized lifestyle counseling in MASLD and early type 2 diabetes, and diagnostic uncertainty in atypical GERD. Conclusions: DRS is a metatranscriptomics-based risk-stratification framework that aggregates active microbial and human pathway signals into interpretable disease-specific risk estimates across a wide range of disease conditions. Validation against self-reported disease labels in an independent cohort shows significant risk enrichment for each of 15 diseases. DRS is intended as an adjunct to clinical evaluation: a decision support tool in situations where routine care encounters uncertainty, delay, or low patient engagement. Future prospective studies using clinically adjudicated endpoints are needed to assess calibration and clinical outcomes.

  • Open Access

    Data-Driven Personalized Nutrition Reduces HbA1c in a Prediabetic and Diabetic Population – a Pilot, Randomized, Placebo-Controlled Clinical Trial

    by Momchilo Vuyisich, Grant Antoine, Morvarid Mehrtash, Hilary Keiser, Janelle Connell, Oyetunji Ogundijo, Nan Shen, Cristina Julian, Madhavi Garimella, Guruduth Banavar, et al.

    Type 2 Diabetes (T2D) is a major public health concern. We have previously shown that the biochemical functions of the gut microbiome contribute to the postprandial glucose response and built a machine learned (ML) model that can personalize dietary choices using a stool metatranscriptomic test. We integrated this data-driven personalized nutrition process into the Viome Precision Nutrition Program (VPNP), which includes sample collection kits (capillary blood and stool), an AI/ML nutritional recommendation engine, and an app for digital delivery of dietary recommendations. To test the efficacy of VPNP, we conducted a decentralized, blinded, randomized, placebo-controlled trial in a prediabetic and diabetic adult population in the USA, with HbA1c as the primary endpoint. For this pilot trial, we recruited 27 participants and randomized them into two arms. The placebo arm included sample collection, digital delivery of the USDA dietary recommendations, and physical delivery of supplements filled with inert material. The VPNP (interventional) arm included digital delivery of data-driven and personalized dietary recommendations, and physical delivery of precision supplements. The nutritional intervention lasted ~90 days. The ANCOVA analysis method was employed to control for potential confounders measured at baseline. VPNP intervention (n=12) reduced HbA1c more than the placebo (n=15) in a clinically significant manner (HbA1c difference of 0.42%, p = 0.028). We demonstrate that a precision nutrition program based on stool and blood metatranscriptomic data and AI/ML analyses can significantly reduce HbA1c relative to USDA recommended nutrition in a prediabetic and diabetic population. These results suggest that integrating data-driven precision nutrition into the healthcare system could reduce the burden of T2D.